ACTRIMS 2023: MS relapse rates with evobrutinib low after 4

Evobrutinib continues to be well tolerated among people with relapsing forms of multiple sclerosis and relapse rates continue to be low.

Related Keywords

California , United States , San Diego , America , Jan Klatt , Merck Kga , Merck Kgaa , Serono , Americas Committee For Treatment , Research In Multiple Sclerosis , Americas Committee , Multiple Sclerosis , Tyrosine Kinase Inhibitor Evobrutinib , Relapsing Multiple Sclerosis Over , Label Extension , North America ,